Form 4: AbbVie Director Thomas C. Freyman Reports Changes in Beneficial Ownership

Director Thomas C. Freyman reports acquisition and disposal of AbbVie common stock and restricted stock units.

Summary

• On May 9, 2025, Thomas C. Freyman, a director of AbbVie Inc., reported changes in his beneficial ownership of AbbVie common stock.
• Freyman acquired 1,203 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program.
• These restricted stock units will be paid in shares of AbbVie common stock on a one-to-one basis upon separation from service, death, or a change in control.
• Freyman also reported indirect ownership of 4,000 shares held by his spouse in a revocable trust, and 1,941 shares each held by his spouse in irrevocable trusts for his sons.
• He disclaims beneficial ownership of the shares held in the trusts.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Future Outlook

The restricted stock units will be paid out in shares of AbbVie common stock upon separation from service, death, or a change in control, as defined in the AbbVie Amended and Restated 2013 Incentive Stock Program.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in company stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the transactions of a company insider.

Key Dates

Keywords

Beneficial Ownership, Form 4, AbbVie, Director, Freyman, Stock